Global Multiple Sclerosis (MS) Drugs Market Research Report 2023

Publication ID:

PB503232494

Publication Date:

March 14, 2023

Pages:

100

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Multiple Sclerosis (MS) Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Multiple Sclerosis (MS) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Multiple Sclerosis (MS) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Multiple Sclerosis (MS) Drugs include Bayer AG, Bayhill Therapeutics, Biogen Idec, Cinnagen, Daiichi Sankyo, Eli Lilly, Fast Forward Llc, Antisense Therapeutics and Apitope, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Multiple Sclerosis (MS) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Sclerosis (MS) Drugs.
The Multiple Sclerosis (MS) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Multiple Sclerosis (MS) Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Sclerosis (MS) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
Segment by Type
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Segment by Application
RRMS
SPMS
PPMS
PRMS
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Multiple Sclerosis (MS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Multiple Sclerosis (MS) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Multiple Sclerosis (MS) Drugs Market Overview
1.1 Product Overview and Scope of Multiple Sclerosis (MS) Drugs
1.2 Multiple Sclerosis (MS) Drugs Segment by Type
1.2.1 Global Multiple Sclerosis (MS) Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.3 Novantrone (Mitoxantrone)
1.2.4 Gilenya (Fingolimod, Fty720)
1.2.5 Aubagio (Teriflunomide)
1.2.6 Tecfidera (Dimethyl Fumarate)
1.2.7 Firategrast (Sb683699, T-0047)
1.2.8 Siponimod (Baf312)
1.2.9 Others
1.3 Multiple Sclerosis (MS) Drugs Segment by Application
1.3.1 Global Multiple Sclerosis (MS) Drugs Market Value by Application: (2023-2029)
1.3.2 RRMS
1.3.3 SPMS
1.3.4 PPMS
1.3.5 PRMS
1.4 Global Multiple Sclerosis (MS) Drugs Market Size Estimates and Forecasts
1.4.1 Global Multiple Sclerosis (MS) Drugs Revenue 2018-2029
1.4.2 Global Multiple Sclerosis (MS) Drugs Sales 2018-2029
1.4.3 Global Multiple Sclerosis (MS) Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Multiple Sclerosis (MS) Drugs Market Competition by Manufacturers
2.1 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Multiple Sclerosis (MS) Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Multiple Sclerosis (MS) Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Product Type & Application
2.7 Multiple Sclerosis (MS) Drugs Market Competitive Situation and Trends
2.7.1 Multiple Sclerosis (MS) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Multiple Sclerosis (MS) Drugs Players Market Share by Revenue
2.7.3 Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Multiple Sclerosis (MS) Drugs Retrospective Market Scenario by Region
3.1 Global Multiple Sclerosis (MS) Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Multiple Sclerosis (MS) Drugs Global Multiple Sclerosis (MS) Drugs Sales by Region: 2018-2029
3.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2018-2023
3.2.2 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2024-2029
3.3 Global Multiple Sclerosis (MS) Drugs Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2018-2029
3.3.1 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2018-2023
3.3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2024-2029
3.4 North America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.4.1 North America Multiple Sclerosis (MS) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2029)
3.4.3 North America Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.5.1 Europe Multiple Sclerosis (MS) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2018-2029)
3.5.3 Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.7.1 Latin America Multiple Sclerosis (MS) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2029)
3.7.3 Latin America Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2018-2029)
4.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2018-2023)
4.1.2 Global Multiple Sclerosis (MS) Drugs Sales by Type (2024-2029)
4.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2018-2029)
4.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2018-2029)
4.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2018-2023)
4.2.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2024-2029)
4.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Multiple Sclerosis (MS) Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2018-2029)
5.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2018-2023)
5.1.2 Global Multiple Sclerosis (MS) Drugs Sales by Application (2024-2029)
5.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2018-2029)
5.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2018-2029)
5.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2018-2023)
5.2.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2024-2029)
5.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Multiple Sclerosis (MS) Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bayer AG
6.1.1 Bayer AG Corporation Information
6.1.2 Bayer AG Description and Business Overview
6.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio
6.1.5 Bayer AG Recent Developments/Updates
6.2 Bayhill Therapeutics
6.2.1 Bayhill Therapeutics Corporation Information
6.2.2 Bayhill Therapeutics Description and Business Overview
6.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.2.5 Bayhill Therapeutics Recent Developments/Updates
6.3 Biogen Idec
6.3.1 Biogen Idec Corporation Information
6.3.2 Biogen Idec Description and Business Overview
6.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio
6.3.5 Biogen Idec Recent Developments/Updates
6.4 Cinnagen
6.4.1 Cinnagen Corporation Information
6.4.2 Cinnagen Description and Business Overview
6.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio
6.4.5 Cinnagen Recent Developments/Updates
6.5 Daiichi Sankyo
6.5.1 Daiichi Sankyo Corporation Information
6.5.2 Daiichi Sankyo Description and Business Overview
6.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio
6.5.5 Daiichi Sankyo Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Fast Forward Llc
6.6.1 Fast Forward Llc Corporation Information
6.6.2 Fast Forward Llc Description and Business Overview
6.6.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio
6.7.5 Fast Forward Llc Recent Developments/Updates
6.8 Antisense Therapeutics
6.8.1 Antisense Therapeutics Corporation Information
6.8.2 Antisense Therapeutics Description and Business Overview
6.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.8.5 Antisense Therapeutics Recent Developments/Updates
6.9 Apitope
6.9.1 Apitope Corporation Information
6.9.2 Apitope Description and Business Overview
6.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Apitope Multiple Sclerosis (MS) Drugs Product Portfolio
6.9.5 Apitope Recent Developments/Updates
6.10 Five Prime Therapeutics
6.10.1 Five Prime Therapeutics Corporation Information
6.10.2 Five Prime Therapeutics Description and Business Overview
6.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.10.5 Five Prime Therapeutics Recent Developments/Updates
6.11 Genmab
6.11.1 Genmab Corporation Information
6.11.2 Genmab Multiple Sclerosis (MS) Drugs Description and Business Overview
6.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Genmab Multiple Sclerosis (MS) Drugs Product Portfolio
6.11.5 Genmab Recent Developments/Updates
6.12 Artielle Immunotherapeutics
6.12.1 Artielle Immunotherapeutics Corporation Information
6.12.2 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Description and Business Overview
6.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.12.5 Artielle Immunotherapeutics Recent Developments/Updates
6.13 Genzyme
6.13.1 Genzyme Corporation Information
6.13.2 Genzyme Multiple Sclerosis (MS) Drugs Description and Business Overview
6.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio
6.13.5 Genzyme Recent Developments/Updates
6.14 Glaxosmithkline
6.14.1 Glaxosmithkline Corporation Information
6.14.2 Glaxosmithkline Multiple Sclerosis (MS) Drugs Description and Business Overview
6.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio
6.14.5 Glaxosmithkline Recent Developments/Updates
6.15 Gw Pharmaceuticals
6.15.1 Gw Pharmaceuticals Corporation Information
6.15.2 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Description and Business Overview
6.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio
6.15.5 Gw Pharmaceuticals Recent Developments/Updates
6.16 Innate Immunotherapeutics
6.16.1 Innate Immunotherapeutics Corporation Information
6.16.2 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Description and Business Overview
6.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.16.5 Innate Immunotherapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Sclerosis (MS) Drugs Industry Chain Analysis
7.2 Multiple Sclerosis (MS) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Sclerosis (MS) Drugs Production Mode & Process
7.4 Multiple Sclerosis (MS) Drugs Sales and Marketing
7.4.1 Multiple Sclerosis (MS) Drugs Sales Channels
7.4.2 Multiple Sclerosis (MS) Drugs Distributors
7.5 Multiple Sclerosis (MS) Drugs Customers
8 Multiple Sclerosis (MS) Drugs Market Dynamics
8.1 Multiple Sclerosis (MS) Drugs Industry Trends
8.2 Multiple Sclerosis (MS) Drugs Market Drivers
8.3 Multiple Sclerosis (MS) Drugs Market Challenges
8.4 Multiple Sclerosis (MS) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂